<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528996</url>
  </required_header>
  <id_info>
    <org_study_id>1205.14</org_study_id>
    <secondary_id>2007-007946-42</secondary_id>
    <nct_id>NCT00528996</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.</brief_title>
  <official_title>A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the bronchodilator efficacy of three doses&#xD;
      (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and&#xD;
      tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives&#xD;
      include comparing the effects on dyspnea and health status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2007</start_date>
  <completion_date type="Actual">May 5, 2009</completion_date>
  <primary_completion_date type="Actual">May 5, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) Response After 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 24.</time_frame>
    <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) Response After 1, 2, 4, 8, 12, and 18 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 1, 2, 4, 8, 12 and 18.</time_frame>
    <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Vital Capacity (FVC) Response After 1, 2, 4, 8, 12, 18, and 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 1, 2, 4, 8, 12, 18, and 24.</time_frame>
    <description>Trough forced vital capacity (FVC) response was defined as the change from baseline in trough FVC. Trough FVC was defined as the mean of the two FVC measurements recorded at the pre-dose measurements (40 and 15 minutes before drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler), which were obtained through spirometry at the same time points as for forced expiratory volume in one second. Baseline FVC was the mean of the two measurements of FVC taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
    <description>Forced expiratory volume in one second (FEV1) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FEV1 AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FEV1. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
    <description>Forced vital capacity (FVC) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FVC AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FVC. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Peak Response After 0, 4, 12, and 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
    <description>Forced expiratory volume in one second (FEV1) peak response after 0, 4, 12, and 24 weeks were reported. Peak FEV1 response was the maximum change from baseline for the post-dose measurements of FEV1. Baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Peak Response After 0, 4, 12, and 24 Weeks</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
    <description>Forced Vital Capacity (FVC) peak response after 0, 4, 12, and 24 weeks were reported. Peak FVC response was the maximum change from baseline for the post-dose measurements of FVC. Baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Forced Expiratory Volume in One Second (FEV1) Measurements at Each Time Point</measure>
    <time_frame>15 minutes (min), 30 min, 1 hour (h), 2 h, 3 h after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24. At 0 min (at drug administration) at Week 4, 12, and 24.</time_frame>
    <description>Individual Forced expiratory volume in one second (FEV1) values measured at each time points at Week 0, 4, 12, and 24 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Forced Vital Capacity (FVC) Measurements at Each Time Point</measure>
    <time_frame>15 minutes (min), 30 min, 1 hour (h), 2 h, 3 h after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24. At 0 min (at drug administration) at Week 4, 12, and 24.</time_frame>
    <description>Individual Forced Vital Capacity (FVC) values measured at each time point at Week 0, 4, 12, and 24 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) Response on Day 3 and 5</measure>
    <time_frame>40 minutes (min) and 15 min before drug administration at Day 1 (baseline) and Day 3 and 5 of treatment period.</time_frame>
    <description>Trough Forced expiratory volume in one second (FEV1) response on Day 3 and 5 are reported, for which the FEV1 response is the change from baseline in trough FEV1. Trough FEV1 for respective day (Day 3 or Day 5)was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler) at that day. Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) at 3 Minutes and 10 Minutes Following Drug Administration</measure>
    <time_frame>3 minutes (min) and 10 after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24.</time_frame>
    <description>Forced expiratory volume in one second (FEV1) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at 3 Minutes and 10 Minutes Following Drug Administration</measure>
    <time_frame>3 minutes (min) and 10 min after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24.</time_frame>
    <description>Forced Vital Capacity (FVC) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>Assessed before drug administration per day during 24 weeks with weekly mean values reporting.</time_frame>
    <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean morning peak expiratory flow rate (PEFR) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Evening Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>Assessed at bed time per day during 24 weeks with weekly mean values reporting.</time_frame>
    <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean of evening peak expiratory flow rate (PEFR) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day (as Occasion Requires (PRN) Salbutamol [Albuterol])</measure>
    <time_frame>Assessed once per day during 24 weeks with weekly mean values reporting.</time_frame>
    <description>The patient recorded the number of occasions salbutamol (albuterol) Metered Dose Inhaler (MDI) was used each day and night during the entire evaluation period. The weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [albuterol]) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation</measure>
    <time_frame>At Week 0, 4, 12, and 24.</time_frame>
    <description>Physicians make a global evaluation reflecting the physician's global opinion of the overall clinical condition of the patient as &quot;poor&quot; (score 1 or 2), &quot;fair&quot; (score 3 or 4), &quot;good&quot; (score 5 or 6), or &quot;excellent&quot; (score 7 or 8). These assessments are made prior to pulmonary function testing and are summarized on pulmonary function test days. This evaluation was based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations. The score ranges from 1 to 8 with higher score indicating better overall clinical condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index - Functional Impairment Domain Score</measure>
    <time_frame>At Week 0 (baseline), 4, 12 and 24.</time_frame>
    <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of functional impairment is reported, which domain score ranges from -3 (major deterioration in the ability of working and doing activities due to shortness of breath; the worst score) to 3 (major improvement in the ability of working and doing activities; mild restriction on full activities due to the improvement of shortness of breath; the best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index - Magnitude of Task Domain Score</measure>
    <time_frame>At week 0 (baseline), 4, 12 and 24</time_frame>
    <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of task is reported, which domain score ranges from -3 (major deterioration from baseline status; the worst score) to 3 (major improvement from baseline status; the best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index - Magnitude of Effort Domain Score</measure>
    <time_frame>At Week 0 (baseline), 4, 12 and 24</time_frame>
    <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of effort is reported, which sub-score ranges from -3 (severe decrease in effort from baseline to avoid shortness of breath. Activities now take 50-100% longer to complete than required at baseline; the worst score) to 3 (Able to do things with much greater effort than previously with few pauses. Activities may be performed 50- 100% more rapidly than at baseline; the best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>At Week 0, 4, 12, and 24.</time_frame>
    <description>The St. George's Respiratory Questionnaire (SGRQ) is a well-established, self-completed tool measuring health-related quality of life in patients with diseases of airways obstruction on three aspects of symptoms, activity, and impacts. The total SGRQ score is reported, which ranges from 0 (the best score) to 100 (the worst score) with smaller score value indicating less limitations due to breathlessness and better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) 8 Domain Scores at Baseline</measure>
    <time_frame>At baseline (Week 0, Day 1 of treatment period).</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function (10 questions), role physical (4 questions), Bodily pain (2 questions), General physical health (5 questions), Vitality (4 questions), Social functioning (2 questions), role emotional (3 questions), and General mental health (5 questions). Each domain score is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the score value, the better the health condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Physical Function Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of physical function (based on 10 questions) is reported, which is the weighted sum of the questions in corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Role Physical Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role limitations due to physical health problems (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitations in roles due to physical health problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Bodily Pain Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of bodily pain (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less severer the bodily pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - General Physical Health Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general physical health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical health in general.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Vitality Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of vitality (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the more vitality and less fatigue one has.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Social Functioning Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of Social functioning (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the social functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - Role Emotional Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role emotional (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitation in roles due to emotional problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item-health Survey (SF-36) - General Mental Health Domain Score</measure>
    <time_frame>At Week 4, 12, and 24.</time_frame>
    <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general mental health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the mental health in general.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>From first does until 30 days after the end of treatment, up to 205 days.</time_frame>
    <description>Number of patients with at least one Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>From first does until 30 days after the end of treatment, up to 205 days.</time_frame>
    <description>Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2080</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEA 2180 BR low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEA 2180 BR medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEA 2180 BR high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium Bromide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEA 2180 BR</intervention_name>
    <description>Solution</description>
    <arm_group_label>BEA 2180 BR high dose</arm_group_label>
    <arm_group_label>BEA 2180 BR low dose</arm_group_label>
    <arm_group_label>BEA 2180 BR medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>Solution</description>
    <arm_group_label>Tiotropium Bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to&#xD;
             participation in the trial, which includes medication washout and restrictions.&#xD;
&#xD;
          2. All patients must have a diagnosis of chronic obstructive pulmonary disease (P95 4381)&#xD;
             and must meet the following spirometric criteria:&#xD;
&#xD;
             Patients must have relatively stable, moderate to severe airway obstruction with an&#xD;
             FEV1 (post-bronchodilator, 30 minutes post salbutamol/albuterol) &lt;80% of predicted&#xD;
             normal and FEV1 less than or equal to 70% of FVC at the PFTs at Visit 1 (screening).&#xD;
&#xD;
          3. Male or female patients 40 years of age or older.&#xD;
&#xD;
          4. Patients must be current or ex-smokers with a smoking history of more than 10 pack&#xD;
             years. Patients who have never smoked cigarettes must be excluded.&#xD;
&#xD;
          5. Patients must be able to perform technically acceptable pulmonary function tests and&#xD;
             electronic PEFR measurements, and must be able to maintain records (Patient Daily&#xD;
             Diary) during the study period as required in the protocol.&#xD;
&#xD;
          6. Patients must be able to inhale medication in a competent manner from the Respimat®&#xD;
             inhaler (Appendix I)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with significant diseases other than COPD will be excluded. A significant&#xD;
             disease is defined as a disease which in the opinion of the investigator may either&#xD;
             put the patient at risk because of participation in the study or a disease which may&#xD;
             influence the results of the study or the patient ability to participate in the study.&#xD;
&#xD;
          2. Patients with clinically relevant abnormal baseline haematology, blood chemistry or&#xD;
             urinalysis, if the abnormality defines a significant disease as defined in exclusion&#xD;
             criterion No. 1.&#xD;
&#xD;
          3. Patients with a recent history (one year or less) of myocardial infarction.&#xD;
&#xD;
          4. Patients with any unstable or life-threatening cardiac arrhythmia.&#xD;
&#xD;
          5. Patients who have been hospitalized for heart failure within the past 3 years.&#xD;
&#xD;
          6. Patients with a malignancy for which the patient has undergone resection, radiation&#xD;
             therapy or chemotherapy within the last five years. Patients with treated basal cell&#xD;
             carcinoma are allowed.&#xD;
&#xD;
          7. Patients with known symptomatic prostatic hyperplasia or bladder neck obstruction as&#xD;
             defined in exclusion criteria No. 1.&#xD;
&#xD;
          8. Patients with known narrow-angle glaucoma.&#xD;
&#xD;
          9. Patients with asthma or a history of asthma.&#xD;
&#xD;
         10. Patients with a history of life-threatening pulmonary obstruction, or a history of&#xD;
             cystic fibrosis or clinically evident bronchiectasis.&#xD;
&#xD;
         11. Patients with known active tuberculosis.&#xD;
&#xD;
         12. Patients with a history of and/or active significant alcohol or drug abuse. See&#xD;
             exclusion criterion No. 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1205.14.061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Downsview</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.150 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.381 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.164 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.167 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.168 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.172 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.175 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.177 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.178 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.377 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.382 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.387 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.388 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.165 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.176 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cottbus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.171 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.379 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.174 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.173 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.375 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.378 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.170 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.384 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.166 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.372 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neumünster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.386 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.385 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oschersleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.169 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.179 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüsselsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.376 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.374 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwetzingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.371 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.373 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.279 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budakeszi</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.273 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.283 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.287 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.286 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cegled</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.281 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.272 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.289 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.271 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.282 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.276 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gödöllö</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.277 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.278 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matrahaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.280 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.285 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.275 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szarvas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.288 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.284 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.274 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.225 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.228 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.227 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seongdong-gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.221 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.222 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.223 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.224 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.226 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuernavaca, Mor. México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hermosillo, Sonora</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Metepec</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey, Nuevo León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zapopan, Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.251 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.253 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.254 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.246 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.241 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.242 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.255 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miechow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.248 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.249 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarnowskie Gory</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.252 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wilkowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.243 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.244 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.245 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.247 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.312 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.313 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.314 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.182 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.186 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.183 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.191 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.181 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Terrassa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.190 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.189 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.187 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1205.14.201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <link>
    <url>http://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>July 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A multinational, randomized, double-blind, placebo-and active-controlled, parallel group efficacy and safety comparison of BEA 2180 to tiotropium and placebo delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD).</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in trial. Subjects visited specialist site to ensure that they met all implemented inclusion criteria. Subjects meeting the exclusion criteria were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>BEA 2180 BR 50 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>BEA 2180 BR 100 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>BEA 2180 BR 200 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Tiotropium Bromide 5 Microgram (mcg)</title>
          <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="415"/>
                <participants group_id="P4" count="390"/>
                <participants group_id="P5" count="427"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="365"/>
                <participants group_id="P2" count="395"/>
                <participants group_id="P3" count="372"/>
                <participants group_id="P4" count="340"/>
                <participants group_id="P5" count="390"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reasons than listing</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused continue medication</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>BEA 2180 BR 50 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>BEA 2180 BR 100 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>BEA 2180 BR 200 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Tiotropium Bromide 5 Microgram (mcg)</title>
          <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="429"/>
            <count group_id="B2" value="419"/>
            <count group_id="B3" value="415"/>
            <count group_id="B4" value="390"/>
            <count group_id="B5" value="427"/>
            <count group_id="B6" value="2080"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.41" spread="8.57"/>
                    <measurement group_id="B2" value="63.98" spread="8.66"/>
                    <measurement group_id="B3" value="64.60" spread="9.11"/>
                    <measurement group_id="B4" value="63.89" spread="8.88"/>
                    <measurement group_id="B5" value="63.91" spread="8.74"/>
                    <measurement group_id="B6" value="64.16" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="146"/>
                    <measurement group_id="B6" value="739"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="269"/>
                    <measurement group_id="B4" value="250"/>
                    <measurement group_id="B5" value="281"/>
                    <measurement group_id="B6" value="1341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="384"/>
                    <measurement group_id="B2" value="371"/>
                    <measurement group_id="B3" value="363"/>
                    <measurement group_id="B4" value="340"/>
                    <measurement group_id="B5" value="382"/>
                    <measurement group_id="B6" value="1840"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in one second (FEV1)</title>
          <description>Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline, Visit 2) prior to administration of the first dose of study medication, which was the mean of the measurements obtaining from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.18" spread="0.46"/>
                    <measurement group_id="B2" value="1.18" spread="0.46"/>
                    <measurement group_id="B3" value="1.18" spread="0.48"/>
                    <measurement group_id="B4" value="1.19" spread="0.49"/>
                    <measurement group_id="B5" value="1.20" spread="0.47"/>
                    <measurement group_id="B6" value="1.18" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) Response After 24 Weeks</title>
        <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) Response After 24 Weeks</title>
          <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.010"/>
                    <measurement group_id="O2" value="0.044" spread="0.010"/>
                    <measurement group_id="O3" value="0.066" spread="0.011"/>
                    <measurement group_id="O4" value="0.087" spread="0.011"/>
                    <measurement group_id="O5" value="0.092" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) Response After 1, 2, 4, 8, 12, and 18 Weeks</title>
        <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 1, 2, 4, 8, 12 and 18.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) Response After 1, 2, 4, 8, 12, and 18 Weeks</title>
          <description>Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.008"/>
                    <measurement group_id="O2" value="0.070" spread="0.008"/>
                    <measurement group_id="O3" value="0.090" spread="0.008"/>
                    <measurement group_id="O4" value="0.106" spread="0.009"/>
                    <measurement group_id="O5" value="0.097" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.009"/>
                    <measurement group_id="O2" value="0.080" spread="0.009"/>
                    <measurement group_id="O3" value="0.094" spread="0.009"/>
                    <measurement group_id="O4" value="0.110" spread="0.009"/>
                    <measurement group_id="O5" value="0.105" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.009"/>
                    <measurement group_id="O2" value="0.066" spread="0.009"/>
                    <measurement group_id="O3" value="0.090" spread="0.009"/>
                    <measurement group_id="O4" value="0.100" spread="0.009"/>
                    <measurement group_id="O5" value="0.099" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.010"/>
                    <measurement group_id="O2" value="0.078" spread="0.010"/>
                    <measurement group_id="O3" value="0.086" spread="0.010"/>
                    <measurement group_id="O4" value="0.101" spread="0.010"/>
                    <measurement group_id="O5" value="0.104" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.010"/>
                    <measurement group_id="O2" value="0.066" spread="0.010"/>
                    <measurement group_id="O3" value="0.083" spread="0.010"/>
                    <measurement group_id="O4" value="0.107" spread="0.010"/>
                    <measurement group_id="O5" value="0.109" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.010"/>
                    <measurement group_id="O2" value="0.063" spread="0.010"/>
                    <measurement group_id="O3" value="0.072" spread="0.010"/>
                    <measurement group_id="O4" value="0.096" spread="0.010"/>
                    <measurement group_id="O5" value="0.096" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Vital Capacity (FVC) Response After 1, 2, 4, 8, 12, 18, and 24 Weeks</title>
        <description>Trough forced vital capacity (FVC) response was defined as the change from baseline in trough FVC. Trough FVC was defined as the mean of the two FVC measurements recorded at the pre-dose measurements (40 and 15 minutes before drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler), which were obtained through spirometry at the same time points as for forced expiratory volume in one second. Baseline FVC was the mean of the two measurements of FVC taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration at baseline (Day 1 of treatment period) and Week 1, 2, 4, 8, 12, 18, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity (FVC) Response After 1, 2, 4, 8, 12, 18, and 24 Weeks</title>
          <description>Trough forced vital capacity (FVC) response was defined as the change from baseline in trough FVC. Trough FVC was defined as the mean of the two FVC measurements recorded at the pre-dose measurements (40 and 15 minutes before drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler), which were obtained through spirometry at the same time points as for forced expiratory volume in one second. Baseline FVC was the mean of the two measurements of FVC taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.015"/>
                    <measurement group_id="O2" value="0.146" spread="0.015"/>
                    <measurement group_id="O3" value="0.172" spread="0.016"/>
                    <measurement group_id="O4" value="0.186" spread="0.016"/>
                    <measurement group_id="O5" value="0.174" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.016"/>
                    <measurement group_id="O2" value="0.166" spread="0.016"/>
                    <measurement group_id="O3" value="0.177" spread="0.016"/>
                    <measurement group_id="O4" value="0.186" spread="0.017"/>
                    <measurement group_id="O5" value="0.188" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.016"/>
                    <measurement group_id="O2" value="0.132" spread="0.016"/>
                    <measurement group_id="O3" value="0.157" spread="0.016"/>
                    <measurement group_id="O4" value="0.156" spread="0.017"/>
                    <measurement group_id="O5" value="0.169" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.018"/>
                    <measurement group_id="O2" value="0.148" spread="0.018"/>
                    <measurement group_id="O3" value="0.166" spread="0.018"/>
                    <measurement group_id="O4" value="0.173" spread="0.018"/>
                    <measurement group_id="O5" value="0.177" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.018"/>
                    <measurement group_id="O2" value="0.121" spread="0.018"/>
                    <measurement group_id="O3" value="0.155" spread="0.018"/>
                    <measurement group_id="O4" value="0.171" spread="0.018"/>
                    <measurement group_id="O5" value="0.178" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.018"/>
                    <measurement group_id="O2" value="0.117" spread="0.018"/>
                    <measurement group_id="O3" value="0.131" spread="0.018"/>
                    <measurement group_id="O4" value="0.153" spread="0.019"/>
                    <measurement group_id="O5" value="0.146" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.044" spread="0.019"/>
                    <measurement group_id="O2" value="0.081" spread="0.019"/>
                    <measurement group_id="O3" value="0.104" spread="0.019"/>
                    <measurement group_id="O4" value="0.132" spread="0.020"/>
                    <measurement group_id="O5" value="0.146" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</title>
        <description>Forced expiratory volume in one second (FEV1) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FEV1 AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FEV1. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</title>
          <description>Forced expiratory volume in one second (FEV1) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FEV1 AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FEV1. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.007"/>
                    <measurement group_id="O2" value="0.172" spread="0.007"/>
                    <measurement group_id="O3" value="0.186" spread="0.007"/>
                    <measurement group_id="O4" value="0.177" spread="0.007"/>
                    <measurement group_id="O5" value="0.165" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.010"/>
                    <measurement group_id="O2" value="0.166" spread="0.010"/>
                    <measurement group_id="O3" value="0.175" spread="0.010"/>
                    <measurement group_id="O4" value="0.165" spread="0.011"/>
                    <measurement group_id="O5" value="0.203" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.011"/>
                    <measurement group_id="O2" value="0.164" spread="0.011"/>
                    <measurement group_id="O3" value="0.166" spread="0.011"/>
                    <measurement group_id="O4" value="0.166" spread="0.011"/>
                    <measurement group_id="O5" value="0.203" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.011"/>
                    <measurement group_id="O2" value="0.140" spread="0.011"/>
                    <measurement group_id="O3" value="0.150" spread="0.011"/>
                    <measurement group_id="O4" value="0.146" spread="0.012"/>
                    <measurement group_id="O5" value="0.177" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</title>
        <description>Forced vital capacity (FVC) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FVC AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FVC. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under the Curve From 0 to 3 Hours (AUC0-3h) Response After 0, 4, 12 and 24 Weeks</title>
          <description>Forced vital capacity (FVC) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FVC AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FVC. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.015"/>
                    <measurement group_id="O2" value="0.321" spread="0.015"/>
                    <measurement group_id="O3" value="0.336" spread="0.015"/>
                    <measurement group_id="O4" value="0.302" spread="0.015"/>
                    <measurement group_id="O5" value="0.312" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.019"/>
                    <measurement group_id="O2" value="0.292" spread="0.019"/>
                    <measurement group_id="O3" value="0.298" spread="0.020"/>
                    <measurement group_id="O4" value="0.247" spread="0.020"/>
                    <measurement group_id="O5" value="0.340" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.020"/>
                    <measurement group_id="O2" value="0.276" spread="0.020"/>
                    <measurement group_id="O3" value="0.278" spread="0.021"/>
                    <measurement group_id="O4" value="0.251" spread="0.021"/>
                    <measurement group_id="O5" value="0.326" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.021"/>
                    <measurement group_id="O2" value="0.233" spread="0.021"/>
                    <measurement group_id="O3" value="0.218" spread="0.022"/>
                    <measurement group_id="O4" value="0.210" spread="0.022"/>
                    <measurement group_id="O5" value="0.274" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Peak Response After 0, 4, 12, and 24 Weeks</title>
        <description>Forced expiratory volume in one second (FEV1) peak response after 0, 4, 12, and 24 weeks were reported. Peak FEV1 response was the maximum change from baseline for the post-dose measurements of FEV1. Baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Peak Response After 0, 4, 12, and 24 Weeks</title>
          <description>Forced expiratory volume in one second (FEV1) peak response after 0, 4, 12, and 24 weeks were reported. Peak FEV1 response was the maximum change from baseline for the post-dose measurements of FEV1. Baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" spread="0.008"/>
                    <measurement group_id="O2" value="0.246" spread="0.008"/>
                    <measurement group_id="O3" value="0.260" spread="0.08"/>
                    <measurement group_id="O4" value="0.266" spread="0.009"/>
                    <measurement group_id="O5" value="0.246" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.090" spread="0.011"/>
                    <measurement group_id="O2" value="0.237" spread="0.011"/>
                    <measurement group_id="O3" value="0.250" spread="0.011"/>
                    <measurement group_id="O4" value="0.243" spread="0.011"/>
                    <measurement group_id="O5" value="0.274" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" spread="0.011"/>
                    <measurement group_id="O2" value="0.236" spread="0.011"/>
                    <measurement group_id="O3" value="0.236" spread="0.012"/>
                    <measurement group_id="O4" value="0.241" spread="0.012"/>
                    <measurement group_id="O5" value="0.273" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.012"/>
                    <measurement group_id="O2" value="0.207" spread="0.012"/>
                    <measurement group_id="O3" value="0.216" spread="0.012"/>
                    <measurement group_id="O4" value="0.216" spread="0.012"/>
                    <measurement group_id="O5" value="0.242" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Peak Response After 0, 4, 12, and 24 Weeks</title>
        <description>Forced Vital Capacity (FVC) peak response after 0, 4, 12, and 24 weeks were reported. Peak FVC response was the maximum change from baseline for the post-dose measurements of FVC. Baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration and 15 min, 30 min, 60 min, 2 hours, 3 hours after drug administration at Week 0 (Day 1 of treatment period), 4, 12, 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Peak Response After 0, 4, 12, and 24 Weeks</title>
          <description>Forced Vital Capacity (FVC) peak response after 0, 4, 12, and 24 weeks were reported. Peak FVC response was the maximum change from baseline for the post-dose measurements of FVC. Baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" spread="0.018"/>
                    <measurement group_id="O2" value="0.474" spread="0.018"/>
                    <measurement group_id="O3" value="0.478" spread="0.018"/>
                    <measurement group_id="O4" value="0.463" spread="0.019"/>
                    <measurement group_id="O5" value="0.463" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.021"/>
                    <measurement group_id="O2" value="0.434" spread="0.021"/>
                    <measurement group_id="O3" value="0.449" spread="0.021"/>
                    <measurement group_id="O4" value="0.386" spread="0.022"/>
                    <measurement group_id="O5" value="0.479" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.177" spread="0.022"/>
                    <measurement group_id="O2" value="0.417" spread="0.022"/>
                    <measurement group_id="O3" value="0.412" spread="0.023"/>
                    <measurement group_id="O4" value="0.384" spread="0.023"/>
                    <measurement group_id="O5" value="0.463" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="0.023"/>
                    <measurement group_id="O2" value="0.369" spread="0.023"/>
                    <measurement group_id="O3" value="0.345" spread="0.023"/>
                    <measurement group_id="O4" value="0.335" spread="0.024"/>
                    <measurement group_id="O5" value="0.393" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Forced Expiratory Volume in One Second (FEV1) Measurements at Each Time Point</title>
        <description>Individual Forced expiratory volume in one second (FEV1) values measured at each time points at Week 0, 4, 12, and 24 were reported.</description>
        <time_frame>15 minutes (min), 30 min, 1 hour (h), 2 h, 3 h after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24. At 0 min (at drug administration) at Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Forced Expiratory Volume in One Second (FEV1) Measurements at Each Time Point</title>
          <description>Individual Forced expiratory volume in one second (FEV1) values measured at each time points at Week 0, 4, 12, and 24 were reported.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - 15 minutes (min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.200" spread="0.006"/>
                    <measurement group_id="O2" value="1.309" spread="0.006"/>
                    <measurement group_id="O3" value="1.310" spread="0.006"/>
                    <measurement group_id="O4" value="1.263" spread="0.006"/>
                    <measurement group_id="O5" value="1.276" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.206" spread="0.007"/>
                    <measurement group_id="O2" value="1.347" spread="0.007"/>
                    <measurement group_id="O3" value="1.357" spread="0.007"/>
                    <measurement group_id="O4" value="1.318" spread="0.007"/>
                    <measurement group_id="O5" value="1.311" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 1 hour (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.223" spread="0.008"/>
                    <measurement group_id="O2" value="1.375" spread="0.008"/>
                    <measurement group_id="O3" value="1.390" spread="0.008"/>
                    <measurement group_id="O4" value="1.369" spread="0.008"/>
                    <measurement group_id="O5" value="1.353" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.212" spread="0.008"/>
                    <measurement group_id="O2" value="1.373" spread="0.008"/>
                    <measurement group_id="O3" value="1.388" spread="0.008"/>
                    <measurement group_id="O4" value="1.395" spread="0.008"/>
                    <measurement group_id="O5" value="1.378" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.220" spread="0.009"/>
                    <measurement group_id="O2" value="1.363" spread="0.009"/>
                    <measurement group_id="O3" value="1.389" spread="0.009"/>
                    <measurement group_id="O4" value="1.403" spread="0.009"/>
                    <measurement group_id="O5" value="1.388" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.163" spread="0.009"/>
                    <measurement group_id="O2" value="1.249" spread="0.009"/>
                    <measurement group_id="O3" value="1.274" spread="0.009"/>
                    <measurement group_id="O4" value="1.284" spread="0.009"/>
                    <measurement group_id="O5" value="1.283" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.187" spread="0.010"/>
                    <measurement group_id="O2" value="1.319" spread="0.010"/>
                    <measurement group_id="O3" value="1.321" spread="0.010"/>
                    <measurement group_id="O4" value="1.279" spread="0.010"/>
                    <measurement group_id="O5" value="1.348" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.200" spread="0.010"/>
                    <measurement group_id="O2" value="1.346" spread="0.010"/>
                    <measurement group_id="O3" value="1.346" spread="0.011"/>
                    <measurement group_id="O4" value="1.308" spread="0.011"/>
                    <measurement group_id="O5" value="1.374" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.207" spread="0.011"/>
                    <measurement group_id="O2" value="1.360" spread="0.011"/>
                    <measurement group_id="O3" value="1.366" spread="0.011"/>
                    <measurement group_id="O4" value="1.350" spread="0.011"/>
                    <measurement group_id="O5" value="1.397" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.211" spread="0.011"/>
                    <measurement group_id="O2" value="1.360" spread="0.011"/>
                    <measurement group_id="O3" value="1.372" spread="0.011"/>
                    <measurement group_id="O4" value="1.372" spread="0.011"/>
                    <measurement group_id="O5" value="1.401" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.211" spread="0.011"/>
                    <measurement group_id="O2" value="1.355" spread="0.011"/>
                    <measurement group_id="O3" value="1.368" spread="0.011"/>
                    <measurement group_id="O4" value="1.380" spread="0.012"/>
                    <measurement group_id="O5" value="1.401" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" spread="0.010"/>
                    <measurement group_id="O2" value="1.249" spread="0.010"/>
                    <measurement group_id="O3" value="1.267" spread="0.010"/>
                    <measurement group_id="O4" value="1.291" spread="0.010"/>
                    <measurement group_id="O5" value="1.293" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.188" spread="0.011"/>
                    <measurement group_id="O2" value="1.321" spread="0.011"/>
                    <measurement group_id="O3" value="1.313" spread="0.011"/>
                    <measurement group_id="O4" value="1.292" spread="0.011"/>
                    <measurement group_id="O5" value="1.354" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.196" spread="0.011"/>
                    <measurement group_id="O2" value="1.348" spread="0.011"/>
                    <measurement group_id="O3" value="1.335" spread="0.011"/>
                    <measurement group_id="O4" value="1.313" spread="0.011"/>
                    <measurement group_id="O5" value="1.371" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.209" spread="0.011"/>
                    <measurement group_id="O2" value="1.358" spread="0.011"/>
                    <measurement group_id="O3" value="1.356" spread="0.011"/>
                    <measurement group_id="O4" value="1.345" spread="0.011"/>
                    <measurement group_id="O5" value="1.391" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.205" spread="0.011"/>
                    <measurement group_id="O2" value="1.357" spread="0.011"/>
                    <measurement group_id="O3" value="1.365" spread="0.011"/>
                    <measurement group_id="O4" value="1.372" spread="0.012"/>
                    <measurement group_id="O5" value="1.401" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.205" spread="0.011"/>
                    <measurement group_id="O2" value="1.352" spread="0.012"/>
                    <measurement group_id="O3" value="1.363" spread="0.012"/>
                    <measurement group_id="O4" value="1.384" spread="0.012"/>
                    <measurement group_id="O5" value="1.401" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.150" spread="0.010"/>
                    <measurement group_id="O2" value="1.227" spread="0.010"/>
                    <measurement group_id="O3" value="1.250" spread="0.011"/>
                    <measurement group_id="O4" value="1.270" spread="0.011"/>
                    <measurement group_id="O5" value="1.276" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 0:15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.164" spread="0.011"/>
                    <measurement group_id="O2" value="1.297" spread="0.011"/>
                    <measurement group_id="O3" value="1.298" spread="0.011"/>
                    <measurement group_id="O4" value="1.278" spread="0.012"/>
                    <measurement group_id="O5" value="1.326" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" spread="0.011"/>
                    <measurement group_id="O2" value="1.318" spread="0.012"/>
                    <measurement group_id="O3" value="1.320" spread="0.012"/>
                    <measurement group_id="O4" value="1.296" spread="0.012"/>
                    <measurement group_id="O5" value="1.355" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.180" spread="0.012"/>
                    <measurement group_id="O2" value="1.338" spread="0.012"/>
                    <measurement group_id="O3" value="1.342" spread="0.012"/>
                    <measurement group_id="O4" value="1.331" spread="0.012"/>
                    <measurement group_id="O5" value="1.368" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.180" spread="0.012"/>
                    <measurement group_id="O2" value="1.332" spread="0.012"/>
                    <measurement group_id="O3" value="1.345" spread="0.012"/>
                    <measurement group_id="O4" value="1.346" spread="0.012"/>
                    <measurement group_id="O5" value="1.373" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.180" spread="0.012"/>
                    <measurement group_id="O2" value="1.326" spread="0.012"/>
                    <measurement group_id="O3" value="1.344" spread="0.012"/>
                    <measurement group_id="O4" value="1.357" spread="0.012"/>
                    <measurement group_id="O5" value="1.370" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Forced Vital Capacity (FVC) Measurements at Each Time Point</title>
        <description>Individual Forced Vital Capacity (FVC) values measured at each time point at Week 0, 4, 12, and 24 were reported.</description>
        <time_frame>15 minutes (min), 30 min, 1 hour (h), 2 h, 3 h after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24. At 0 min (at drug administration) at Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Forced Vital Capacity (FVC) Measurements at Each Time Point</title>
          <description>Individual Forced Vital Capacity (FVC) values measured at each time point at Week 0, 4, 12, and 24 were reported.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - 15 minutes (min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.572" spread="0.013"/>
                    <measurement group_id="O2" value="2.787" spread="0.013"/>
                    <measurement group_id="O3" value="2.778" spread="0.013"/>
                    <measurement group_id="O4" value="2.691" spread="0.013"/>
                    <measurement group_id="O5" value="2.729" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.589" spread="0.015"/>
                    <measurement group_id="O2" value="2.854" spread="0.015"/>
                    <measurement group_id="O3" value="2.852" spread="0.015"/>
                    <measurement group_id="O4" value="2.776" spread="0.016"/>
                    <measurement group_id="O5" value="2.802" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 1 hour (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" spread="0.016"/>
                    <measurement group_id="O2" value="2.885" spread="0.017"/>
                    <measurement group_id="O3" value="2.907" spread="0.017"/>
                    <measurement group_id="O4" value="2.853" spread="0.017"/>
                    <measurement group_id="O5" value="2.864" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.598" spread="0.017"/>
                    <measurement group_id="O2" value="2.881" spread="0.017"/>
                    <measurement group_id="O3" value="2.896" spread="0.018"/>
                    <measurement group_id="O4" value="2.886" spread="0.018"/>
                    <measurement group_id="O5" value="2.885" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" spread="0.019"/>
                    <measurement group_id="O2" value="2.867" spread="0.019"/>
                    <measurement group_id="O3" value="2.896" spread="0.019"/>
                    <measurement group_id="O4" value="2.896" spread="0.019"/>
                    <measurement group_id="O5" value="2.901" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 0 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.510" spread="0.016"/>
                    <measurement group_id="O2" value="2.665" spread="0.016"/>
                    <measurement group_id="O3" value="2.689" spread="0.016"/>
                    <measurement group_id="O4" value="2.688" spread="0.017"/>
                    <measurement group_id="O5" value="2.702" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.547" spread="0.019"/>
                    <measurement group_id="O2" value="2.770" spread="0.019"/>
                    <measurement group_id="O3" value="2.776" spread="0.019"/>
                    <measurement group_id="O4" value="2.670" spread="0.019"/>
                    <measurement group_id="O5" value="2.822" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.575" spread="0.020"/>
                    <measurement group_id="O2" value="2.812" spread="0.020"/>
                    <measurement group_id="O3" value="2.803" spread="0.020"/>
                    <measurement group_id="O4" value="2.711" spread="0.020"/>
                    <measurement group_id="O5" value="2.852" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.590" spread="0.020"/>
                    <measurement group_id="O2" value="2.842" spread="0.020"/>
                    <measurement group_id="O3" value="2.848" spread="0.021"/>
                    <measurement group_id="O4" value="2.779" spread="0.021"/>
                    <measurement group_id="O5" value="2.891" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.592" spread="0.021"/>
                    <measurement group_id="O2" value="2.842" spread="0.021"/>
                    <measurement group_id="O3" value="2.851" spread="0.021"/>
                    <measurement group_id="O4" value="2.815" spread="0.022"/>
                    <measurement group_id="O5" value="2.893" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.595" spread="0.021"/>
                    <measurement group_id="O2" value="2.842" spread="0.021"/>
                    <measurement group_id="O3" value="2.849" spread="0.022"/>
                    <measurement group_id="O4" value="2.837" spread="0.022"/>
                    <measurement group_id="O5" value="2.891" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.533" spread="0.018"/>
                    <measurement group_id="O2" value="2.654" spread="0.018"/>
                    <measurement group_id="O3" value="2.687" spread="0.018"/>
                    <measurement group_id="O4" value="2.703" spread="0.018"/>
                    <measurement group_id="O5" value="2.711" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.563" spread="0.020"/>
                    <measurement group_id="O2" value="2.764" spread="0.020"/>
                    <measurement group_id="O3" value="2.751" spread="0.020"/>
                    <measurement group_id="O4" value="2.688" spread="0.021"/>
                    <measurement group_id="O5" value="2.803" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.574" spread="0.020"/>
                    <measurement group_id="O2" value="2.796" spread="0.020"/>
                    <measurement group_id="O3" value="2.788" spread="0.021"/>
                    <measurement group_id="O4" value="2.720" spread="0.021"/>
                    <measurement group_id="O5" value="2.844" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.606" spread="0.021"/>
                    <measurement group_id="O2" value="2.823" spread="0.021"/>
                    <measurement group_id="O3" value="2.821" spread="0.022"/>
                    <measurement group_id="O4" value="2.773" spread="0.022"/>
                    <measurement group_id="O5" value="2.866" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.584" spread="0.022"/>
                    <measurement group_id="O2" value="2.828" spread="0.022"/>
                    <measurement group_id="O3" value="2.829" spread="0.022"/>
                    <measurement group_id="O4" value="2.820" spread="0.023"/>
                    <measurement group_id="O5" value="2.878" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.588" spread="0.022"/>
                    <measurement group_id="O2" value="2.819" spread="0.022"/>
                    <measurement group_id="O3" value="2.836" spread="0.022"/>
                    <measurement group_id="O4" value="2.840" spread="0.023"/>
                    <measurement group_id="O5" value="2.886" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.489" spread="0.019"/>
                    <measurement group_id="O2" value="2.614" spread="0.019"/>
                    <measurement group_id="O3" value="2.637" spread="0.019"/>
                    <measurement group_id="O4" value="2.664" spread="0.020"/>
                    <measurement group_id="O5" value="2.678" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.504" spread="0.021"/>
                    <measurement group_id="O2" value="2.725" spread="0.021"/>
                    <measurement group_id="O3" value="2.705" spread="0.021"/>
                    <measurement group_id="O4" value="2.667" spread="0.022"/>
                    <measurement group_id="O5" value="2.761" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24- 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.520" spread="0.022"/>
                    <measurement group_id="O2" value="2.753" spread="0.022"/>
                    <measurement group_id="O3" value="2.724" spread="0.022"/>
                    <measurement group_id="O4" value="2.690" spread="0.022"/>
                    <measurement group_id="O5" value="2.803" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.539" spread="0.022"/>
                    <measurement group_id="O2" value="2.793" spread="0.022"/>
                    <measurement group_id="O3" value="2.763" spread="0.022"/>
                    <measurement group_id="O4" value="2.739" spread="0.023"/>
                    <measurement group_id="O5" value="2.823" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.533" spread="0.023"/>
                    <measurement group_id="O2" value="2.778" spread="0.023"/>
                    <measurement group_id="O3" value="2.770" spread="0.023"/>
                    <measurement group_id="O4" value="2.771" spread="0.023"/>
                    <measurement group_id="O5" value="2.822" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 3 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.547" spread="0.023"/>
                    <measurement group_id="O2" value="2.769" spread="0.024"/>
                    <measurement group_id="O3" value="2.766" spread="0.024"/>
                    <measurement group_id="O4" value="2.789" spread="0.024"/>
                    <measurement group_id="O5" value="2.806" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) Response on Day 3 and 5</title>
        <description>Trough Forced expiratory volume in one second (FEV1) response on Day 3 and 5 are reported, for which the FEV1 response is the change from baseline in trough FEV1. Trough FEV1 for respective day (Day 3 or Day 5)was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler) at that day. Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
        <time_frame>40 minutes (min) and 15 min before drug administration at Day 1 (baseline) and Day 3 and 5 of treatment period.</time_frame>
        <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) Response on Day 3 and 5</title>
          <description>Trough Forced expiratory volume in one second (FEV1) response on Day 3 and 5 are reported, for which the FEV1 response is the change from baseline in trough FEV1. Trough FEV1 for respective day (Day 3 or Day 5)was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler) at that day. Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.</description>
          <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.026"/>
                    <measurement group_id="O2" value="0.060" spread="0.025"/>
                    <measurement group_id="O3" value="0.101" spread="0.025"/>
                    <measurement group_id="O4" value="0.124" spread="0.026"/>
                    <measurement group_id="O5" value="0.103" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.023"/>
                    <measurement group_id="O2" value="0.041" spread="0.023"/>
                    <measurement group_id="O3" value="0.095" spread="0.023"/>
                    <measurement group_id="O4" value="0.115" spread="0.24"/>
                    <measurement group_id="O5" value="0.118" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) at 3 Minutes and 10 Minutes Following Drug Administration</title>
        <description>Forced expiratory volume in one second (FEV1) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
        <time_frame>3 minutes (min) and 10 after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24.</time_frame>
        <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) at 3 Minutes and 10 Minutes Following Drug Administration</title>
          <description>Forced expiratory volume in one second (FEV1) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
          <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - 3 minutes (min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.128" spread="0.015"/>
                    <measurement group_id="O2" value="1.195" spread="0.015"/>
                    <measurement group_id="O3" value="1.185" spread="0.015"/>
                    <measurement group_id="O4" value="1.147" spread="0.015"/>
                    <measurement group_id="O5" value="1.206" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 -10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.135" spread="0.018"/>
                    <measurement group_id="O2" value="1.253" spread="0.017"/>
                    <measurement group_id="O3" value="1.268" spread="0.017"/>
                    <measurement group_id="O4" value="1.224" spread="0.018"/>
                    <measurement group_id="O5" value="1.247" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.161" spread="0.026"/>
                    <measurement group_id="O2" value="1.208" spread="0.025"/>
                    <measurement group_id="O3" value="1.259" spread="0.025"/>
                    <measurement group_id="O4" value="1.227" spread="0.026"/>
                    <measurement group_id="O5" value="1.260" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.160" spread="0.028"/>
                    <measurement group_id="O2" value="1.252" spread="0.027"/>
                    <measurement group_id="O3" value="1.312" spread="0.028"/>
                    <measurement group_id="O4" value="1.252" spread="0.028"/>
                    <measurement group_id="O5" value="1.301" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.151" spread="0.028"/>
                    <measurement group_id="O2" value="1.233" spread="0.027"/>
                    <measurement group_id="O3" value="1.251" spread="0.027"/>
                    <measurement group_id="O4" value="1.258" spread="0.028"/>
                    <measurement group_id="O5" value="1.310" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.172" spread="0.027"/>
                    <measurement group_id="O2" value="1.258" spread="0.027"/>
                    <measurement group_id="O3" value="1.304" spread="0.027"/>
                    <measurement group_id="O4" value="1.279" spread="0.027"/>
                    <measurement group_id="O5" value="1.336" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.115" spread="0.029"/>
                    <measurement group_id="O2" value="1.196" spread="0.029"/>
                    <measurement group_id="O3" value="1.230" spread="0.029"/>
                    <measurement group_id="O4" value="1.211" spread="0.030"/>
                    <measurement group_id="O5" value="1.301" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.138" spread="0.032"/>
                    <measurement group_id="O2" value="1.240" spread="0.031"/>
                    <measurement group_id="O3" value="1.278" spread="0.031"/>
                    <measurement group_id="O4" value="1.244" spread="0.032"/>
                    <measurement group_id="O5" value="1.329" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at 3 Minutes and 10 Minutes Following Drug Administration</title>
        <description>Forced Vital Capacity (FVC) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
        <time_frame>3 minutes (min) and 10 min after drug administration at Week 0 (Day 1 of treatment period), 4, 12, and 24.</time_frame>
        <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at 3 Minutes and 10 Minutes Following Drug Administration</title>
          <description>Forced Vital Capacity (FVC) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.</description>
          <population>Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - 3 minutes (min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.381" spread="0.028"/>
                    <measurement group_id="O2" value="2.530" spread="0.027"/>
                    <measurement group_id="O3" value="2.535" spread="0.027"/>
                    <measurement group_id="O4" value="2.455" spread="0.028"/>
                    <measurement group_id="O5" value="2.500" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.392" spread="0.034"/>
                    <measurement group_id="O2" value="2.624" spread="0.033"/>
                    <measurement group_id="O3" value="2.658" spread="0.033"/>
                    <measurement group_id="O4" value="2.557" spread="0.034"/>
                    <measurement group_id="O5" value="2.593" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.391" spread="0.044"/>
                    <measurement group_id="O2" value="2.623" spread="0.043"/>
                    <measurement group_id="O3" value="2.638" spread="0.044"/>
                    <measurement group_id="O4" value="2.523" spread="0.044"/>
                    <measurement group_id="O5" value="2.601" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.391" spread="0.049"/>
                    <measurement group_id="O2" value="2.693" spread="0.048"/>
                    <measurement group_id="O3" value="2.697" spread="0.048"/>
                    <measurement group_id="O4" value="2.540" spread="0.049"/>
                    <measurement group_id="O5" value="2.634" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.395" spread="0.048"/>
                    <measurement group_id="O2" value="2.594" spread="0.047"/>
                    <measurement group_id="O3" value="2.604" spread="0.048"/>
                    <measurement group_id="O4" value="2.549" spread="0.049"/>
                    <measurement group_id="O5" value="2.631" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.417" spread="0.050"/>
                    <measurement group_id="O2" value="2.648" spread="0.049"/>
                    <measurement group_id="O3" value="2.637" spread="0.049"/>
                    <measurement group_id="O4" value="2.579" spread="0.050"/>
                    <measurement group_id="O5" value="2.646" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 3 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.355" spread="0.054"/>
                    <measurement group_id="O2" value="2.566" spread="0.053"/>
                    <measurement group_id="O3" value="2.556" spread="0.053"/>
                    <measurement group_id="O4" value="2.513" spread="0.054"/>
                    <measurement group_id="O5" value="2.624" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.403" spread="0.058"/>
                    <measurement group_id="O2" value="2.635" spread="0.057"/>
                    <measurement group_id="O3" value="2.599" spread="0.057"/>
                    <measurement group_id="O4" value="2.545" spread="0.058"/>
                    <measurement group_id="O5" value="2.664" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR)</title>
        <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean morning peak expiratory flow rate (PEFR) is reported.</description>
        <time_frame>Assessed before drug administration per day during 24 weeks with weekly mean values reporting.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR)</title>
          <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean morning peak expiratory flow rate (PEFR) is reported.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litres/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.41" spread="1.629"/>
                    <measurement group_id="O2" value="177.03" spread="1.641"/>
                    <measurement group_id="O3" value="176.20" spread="1.658"/>
                    <measurement group_id="O4" value="179.46" spread="1.718"/>
                    <measurement group_id="O5" value="177.54" spread="1.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.34" spread="1.917"/>
                    <measurement group_id="O2" value="177.64" spread="1.932"/>
                    <measurement group_id="O3" value="175.82" spread="1.952"/>
                    <measurement group_id="O4" value="179.24" spread="2.023"/>
                    <measurement group_id="O5" value="176.46" spread="1.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.53" spread="1.957"/>
                    <measurement group_id="O2" value="177.19" spread="1.972"/>
                    <measurement group_id="O3" value="177.38" spread="1.993"/>
                    <measurement group_id="O4" value="178.94" spread="2.067"/>
                    <measurement group_id="O5" value="175.49" spread="1.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.82" spread="2.006"/>
                    <measurement group_id="O2" value="174.99" spread="2.021"/>
                    <measurement group_id="O3" value="176.37" spread="2.042"/>
                    <measurement group_id="O4" value="178.06" spread="2.118"/>
                    <measurement group_id="O5" value="175.17" spread="2.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.00" spread="1.983"/>
                    <measurement group_id="O2" value="176.16" spread="1.998"/>
                    <measurement group_id="O3" value="176.90" spread="2.019"/>
                    <measurement group_id="O4" value="178.29" spread="2.094"/>
                    <measurement group_id="O5" value="176.32" spread="1.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.31" spread="2.058"/>
                    <measurement group_id="O2" value="176.26" spread="2.073"/>
                    <measurement group_id="O3" value="175.31" spread="2.095"/>
                    <measurement group_id="O4" value="177.59" spread="2.172"/>
                    <measurement group_id="O5" value="175.09" spread="2.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.30" spread="2.033"/>
                    <measurement group_id="O2" value="175.71" spread="2.049"/>
                    <measurement group_id="O3" value="174.35" spread="2.070"/>
                    <measurement group_id="O4" value="175.85" spread="2.147"/>
                    <measurement group_id="O5" value="175.50" spread="2.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.83" spread="2.085"/>
                    <measurement group_id="O2" value="173.99" spread="2.101"/>
                    <measurement group_id="O3" value="173.95" spread="2.123"/>
                    <measurement group_id="O4" value="176.41" spread="2.201"/>
                    <measurement group_id="O5" value="174.71" spread="2.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.89" spread="2.156"/>
                    <measurement group_id="O2" value="175.74" spread="2.171"/>
                    <measurement group_id="O3" value="172.84" spread="2.194"/>
                    <measurement group_id="O4" value="177.35" spread="2.274"/>
                    <measurement group_id="O5" value="174.75" spread="2.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.74" spread="2.126"/>
                    <measurement group_id="O2" value="173.63" spread="2.142"/>
                    <measurement group_id="O3" value="171.24" spread="2.164"/>
                    <measurement group_id="O4" value="176.14" spread="2.242"/>
                    <measurement group_id="O5" value="174.71" spread="2.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.98" spread="2.165"/>
                    <measurement group_id="O2" value="173.45" spread="2.181"/>
                    <measurement group_id="O3" value="169.92" spread="2.204"/>
                    <measurement group_id="O4" value="174.05" spread="2.283"/>
                    <measurement group_id="O5" value="174.82" spread="2.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.91" spread="2.192"/>
                    <measurement group_id="O2" value="174.72" spread="2.209"/>
                    <measurement group_id="O3" value="169.90" spread="2.232"/>
                    <measurement group_id="O4" value="175.40" spread="2.316"/>
                    <measurement group_id="O5" value="174.63" spread="2.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.22" spread="2.093"/>
                    <measurement group_id="O2" value="173.59" spread="2.109"/>
                    <measurement group_id="O3" value="169.96" spread="2.131"/>
                    <measurement group_id="O4" value="175.51" spread="2.211"/>
                    <measurement group_id="O5" value="175.97" spread="2.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.66" spread="2.165"/>
                    <measurement group_id="O2" value="172.29" spread="2.181"/>
                    <measurement group_id="O3" value="168.51" spread="2.203"/>
                    <measurement group_id="O4" value="175.65" spread="2.283"/>
                    <measurement group_id="O5" value="174.86" spread="2.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.78" spread="2.196"/>
                    <measurement group_id="O2" value="171.12" spread="2.213"/>
                    <measurement group_id="O3" value="168.69" spread="2.236"/>
                    <measurement group_id="O4" value="175.01" spread="2.318"/>
                    <measurement group_id="O5" value="174.03" spread="2.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.76" spread="2.206"/>
                    <measurement group_id="O2" value="170.92" spread="2.223"/>
                    <measurement group_id="O3" value="169.26" spread="2.246"/>
                    <measurement group_id="O4" value="174.07" spread="2.330"/>
                    <measurement group_id="O5" value="174.23" spread="2.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.59" spread="2.267"/>
                    <measurement group_id="O2" value="171.32" spread="2.285"/>
                    <measurement group_id="O3" value="169.53" spread="2.309"/>
                    <measurement group_id="O4" value="174.89" spread="2.396"/>
                    <measurement group_id="O5" value="174.04" spread="2.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.04" spread="2.248"/>
                    <measurement group_id="O2" value="169.36" spread="2.266"/>
                    <measurement group_id="O3" value="168.95" spread="2.289"/>
                    <measurement group_id="O4" value="173.59" spread="2.376"/>
                    <measurement group_id="O5" value="171.90" spread="2.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.37" spread="2.263"/>
                    <measurement group_id="O2" value="169.24" spread="2.280"/>
                    <measurement group_id="O3" value="170.45" spread="2.304"/>
                    <measurement group_id="O4" value="175.29" spread="2.389"/>
                    <measurement group_id="O5" value="172.92" spread="2.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.77" spread="2.291"/>
                    <measurement group_id="O2" value="169.31" spread="2.309"/>
                    <measurement group_id="O3" value="169.84" spread="2.332"/>
                    <measurement group_id="O4" value="174.81" spread="2.420"/>
                    <measurement group_id="O5" value="173.31" spread="2.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.47" spread="2.276"/>
                    <measurement group_id="O2" value="169.30" spread="2.293"/>
                    <measurement group_id="O3" value="169.12" spread="2.317"/>
                    <measurement group_id="O4" value="175.43" spread="2.404"/>
                    <measurement group_id="O5" value="172.77" spread="2.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.85" spread="2.267"/>
                    <measurement group_id="O2" value="167.60" spread="2.284"/>
                    <measurement group_id="O3" value="169.29" spread="2.308"/>
                    <measurement group_id="O4" value="175.12" spread="2.393"/>
                    <measurement group_id="O5" value="171.93" spread="2.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.41" spread="2.303"/>
                    <measurement group_id="O2" value="167.38" spread="2.320"/>
                    <measurement group_id="O3" value="167.26" spread="2.345"/>
                    <measurement group_id="O4" value="174.30" spread="2.430"/>
                    <measurement group_id="O5" value="171.13" spread="2.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.15" spread="2.311"/>
                    <measurement group_id="O2" value="167.08" spread="2.329"/>
                    <measurement group_id="O3" value="165.87" spread="2.353"/>
                    <measurement group_id="O4" value="176.36" spread="2.441"/>
                    <measurement group_id="O5" value="171.53" spread="2.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Evening Peak Expiratory Flow Rate (PEFR)</title>
        <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean of evening peak expiratory flow rate (PEFR) is reported.</description>
        <time_frame>Assessed at bed time per day during 24 weeks with weekly mean values reporting.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Evening Peak Expiratory Flow Rate (PEFR)</title>
          <description>The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean of evening peak expiratory flow rate (PEFR) is reported.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>litres/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.64" spread="1.467"/>
                    <measurement group_id="O2" value="186.40" spread="1.463"/>
                    <measurement group_id="O3" value="186.37" spread="1.467"/>
                    <measurement group_id="O4" value="187.31" spread="1.542"/>
                    <measurement group_id="O5" value="187.13" spread="1.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.18" spread="1.694"/>
                    <measurement group_id="O2" value="187.16" spread="1.690"/>
                    <measurement group_id="O3" value="185.96" spread="1.694"/>
                    <measurement group_id="O4" value="187.16" spread="1.782"/>
                    <measurement group_id="O5" value="185.79" spread="1.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.85" spread="1.761"/>
                    <measurement group_id="O2" value="187.14" spread="1.756"/>
                    <measurement group_id="O3" value="183.77" spread="1.761"/>
                    <measurement group_id="O4" value="187.41" spread="1.851"/>
                    <measurement group_id="O5" value="185.61" spread="1.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.91" spread="1.858"/>
                    <measurement group_id="O2" value="186.96" spread="1.853"/>
                    <measurement group_id="O3" value="184.33" spread="1.858"/>
                    <measurement group_id="O4" value="187.11" spread="1.952"/>
                    <measurement group_id="O5" value="185.23" spread="1.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.33" spread="1.921"/>
                    <measurement group_id="O2" value="186.03" spread="1.915"/>
                    <measurement group_id="O3" value="186.84" spread="1.920"/>
                    <measurement group_id="O4" value="185.67" spread="2.017"/>
                    <measurement group_id="O5" value="185.02" spread="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.29" spread="2.009"/>
                    <measurement group_id="O2" value="183.97" spread="2.004"/>
                    <measurement group_id="O3" value="185.32" spread="2.009"/>
                    <measurement group_id="O4" value="184.51" spread="2.110"/>
                    <measurement group_id="O5" value="184.34" spread="1.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.10" spread="1.989"/>
                    <measurement group_id="O2" value="183.82" spread="1.984"/>
                    <measurement group_id="O3" value="184.57" spread="1.989"/>
                    <measurement group_id="O4" value="182.39" spread="2.090"/>
                    <measurement group_id="O5" value="183.80" spread="1.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.98" spread="1.975"/>
                    <measurement group_id="O2" value="183.69" spread="1.970"/>
                    <measurement group_id="O3" value="182.81" spread="1.975"/>
                    <measurement group_id="O4" value="182.01" spread="2.076"/>
                    <measurement group_id="O5" value="181.66" spread="1.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.67" spread="2.033"/>
                    <measurement group_id="O2" value="182.98" spread="2.028"/>
                    <measurement group_id="O3" value="181.88" spread="2.033"/>
                    <measurement group_id="O4" value="184.21" spread="2.136"/>
                    <measurement group_id="O5" value="183.38" spread="2.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.15" spread="2.067"/>
                    <measurement group_id="O2" value="181.90" spread="2.062"/>
                    <measurement group_id="O3" value="179.46" spread="2.067"/>
                    <measurement group_id="O4" value="182.53" spread="2.170"/>
                    <measurement group_id="O5" value="182.12" spread="2.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.02" spread="2.122"/>
                    <measurement group_id="O2" value="182.05" spread="2.117"/>
                    <measurement group_id="O3" value="179.36" spread="2.122"/>
                    <measurement group_id="O4" value="182.54" spread="2.227"/>
                    <measurement group_id="O5" value="181.58" spread="2.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.84" spread="2.169"/>
                    <measurement group_id="O2" value="180.46" spread="2.163"/>
                    <measurement group_id="O3" value="179.65" spread="2.169"/>
                    <measurement group_id="O4" value="180.52" spread="2.281"/>
                    <measurement group_id="O5" value="181.09" spread="2.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.95" spread="2.162"/>
                    <measurement group_id="O2" value="180.80" spread="2.156"/>
                    <measurement group_id="O3" value="178.40" spread="2.162"/>
                    <measurement group_id="O4" value="181.12" spread="2.270"/>
                    <measurement group_id="O5" value="183.50" spread="2.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.72" spread="2.168"/>
                    <measurement group_id="O2" value="179.23" spread="2.162"/>
                    <measurement group_id="O3" value="177.70" spread="2.168"/>
                    <measurement group_id="O4" value="181.26" spread="2.278"/>
                    <measurement group_id="O5" value="183.27" spread="2.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.77" spread="2.193"/>
                    <measurement group_id="O2" value="178.86" spread="2.187"/>
                    <measurement group_id="O3" value="177.33" spread="2.193"/>
                    <measurement group_id="O4" value="181.66" spread="2.304"/>
                    <measurement group_id="O5" value="182.12" spread="2.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.50" spread="2.227"/>
                    <measurement group_id="O2" value="179.17" spread="2.220"/>
                    <measurement group_id="O3" value="177.30" spread="2.226"/>
                    <measurement group_id="O4" value="180.18" spread="2.342"/>
                    <measurement group_id="O5" value="180.76" spread="2.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.12" spread="2.199"/>
                    <measurement group_id="O2" value="179.50" spread="2.193"/>
                    <measurement group_id="O3" value="177.51" spread="2.198"/>
                    <measurement group_id="O4" value="178.95" spread="2.314"/>
                    <measurement group_id="O5" value="180.40" spread="2.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.66" spread="2.206"/>
                    <measurement group_id="O2" value="177.88" spread="2.200"/>
                    <measurement group_id="O3" value="176.28" spread="2.206"/>
                    <measurement group_id="O4" value="178.92" spread="2.321"/>
                    <measurement group_id="O5" value="179.47" spread="2.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.70" spread="2.229"/>
                    <measurement group_id="O2" value="177.34" spread="2.223"/>
                    <measurement group_id="O3" value="177.78" spread="2.229"/>
                    <measurement group_id="O4" value="178.64" spread="2.342"/>
                    <measurement group_id="O5" value="179.98" spread="2.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.54" spread="2.322"/>
                    <measurement group_id="O2" value="177.50" spread="2.316"/>
                    <measurement group_id="O3" value="177.23" spread="2.322"/>
                    <measurement group_id="O4" value="179.20" spread="2.441"/>
                    <measurement group_id="O5" value="180.70" spread="2.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.13" spread="2.307"/>
                    <measurement group_id="O2" value="175.87" spread="2.300"/>
                    <measurement group_id="O3" value="176.16" spread="2.306"/>
                    <measurement group_id="O4" value="178.87" spread="2.424"/>
                    <measurement group_id="O5" value="179.66" spread="2.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.32" spread="2.309"/>
                    <measurement group_id="O2" value="174.78" spread="2.302"/>
                    <measurement group_id="O3" value="175.23" spread="2.308"/>
                    <measurement group_id="O4" value="177.71" spread="2.424"/>
                    <measurement group_id="O5" value="178.98" spread="2.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.75" spread="2.316"/>
                    <measurement group_id="O2" value="174.37" spread="2.310"/>
                    <measurement group_id="O3" value="176.10" spread="2.316"/>
                    <measurement group_id="O4" value="177.54" spread="2.434"/>
                    <measurement group_id="O5" value="178.20" spread="2.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.69" spread="2.356"/>
                    <measurement group_id="O2" value="172.72" spread="2.349"/>
                    <measurement group_id="O3" value="176.20" spread="2.356"/>
                    <measurement group_id="O4" value="179.04" spread="2.475"/>
                    <measurement group_id="O5" value="178.21" spread="2.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day (as Occasion Requires (PRN) Salbutamol [Albuterol])</title>
        <description>The patient recorded the number of occasions salbutamol (albuterol) Metered Dose Inhaler (MDI) was used each day and night during the entire evaluation period. The weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [albuterol]) is reported.</description>
        <time_frame>Assessed once per day during 24 weeks with weekly mean values reporting.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day (as Occasion Requires (PRN) Salbutamol [Albuterol])</title>
          <description>The patient recorded the number of occasions salbutamol (albuterol) Metered Dose Inhaler (MDI) was used each day and night during the entire evaluation period. The weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [albuterol]) is reported.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>Metered Dose Inhaler use per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.514" spread="0.075"/>
                    <measurement group_id="O2" value="1.964" spread="0.075"/>
                    <measurement group_id="O3" value="1.972" spread="0.076"/>
                    <measurement group_id="O4" value="1.790" spread="0.078"/>
                    <measurement group_id="O5" value="2.084" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.524" spread="0.079"/>
                    <measurement group_id="O2" value="1.985" spread="0.079"/>
                    <measurement group_id="O3" value="2.044" spread="0.080"/>
                    <measurement group_id="O4" value="1.803" spread="0.082"/>
                    <measurement group_id="O5" value="2.109" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.509" spread="0.081"/>
                    <measurement group_id="O2" value="1.960" spread="0.081"/>
                    <measurement group_id="O3" value="2.037" spread="0.081"/>
                    <measurement group_id="O4" value="1.835" spread="0.084"/>
                    <measurement group_id="O5" value="2.093" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.498" spread="0.081"/>
                    <measurement group_id="O2" value="1.977" spread="0.081"/>
                    <measurement group_id="O3" value="2.017" spread="0.082"/>
                    <measurement group_id="O4" value="1.885" spread="0.085"/>
                    <measurement group_id="O5" value="2.118" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.548" spread="0.086"/>
                    <measurement group_id="O2" value="2.040" spread="0.085"/>
                    <measurement group_id="O3" value="2.012" spread="0.086"/>
                    <measurement group_id="O4" value="1.768" spread="0.089"/>
                    <measurement group_id="O5" value="2.106" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.629" spread="0.088"/>
                    <measurement group_id="O2" value="2.048" spread="0.088"/>
                    <measurement group_id="O3" value="2.041" spread="0.088"/>
                    <measurement group_id="O4" value="1.789" spread="0.091"/>
                    <measurement group_id="O5" value="2.116" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.656" spread="0.088"/>
                    <measurement group_id="O2" value="2.042" spread="0.088"/>
                    <measurement group_id="O3" value="2.039" spread="0.088"/>
                    <measurement group_id="O4" value="1.851" spread="0.091"/>
                    <measurement group_id="O5" value="2.122" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.612" spread="0.089"/>
                    <measurement group_id="O2" value="2.007" spread="0.088"/>
                    <measurement group_id="O3" value="2.010" spread="0.089"/>
                    <measurement group_id="O4" value="1.877" spread="0.092"/>
                    <measurement group_id="O5" value="2.129" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" spread="0.088"/>
                    <measurement group_id="O2" value="2.026" spread="0.088"/>
                    <measurement group_id="O3" value="1.981" spread="0.089"/>
                    <measurement group_id="O4" value="1.834" spread="0.092"/>
                    <measurement group_id="O5" value="2.094" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.623" spread="0.090"/>
                    <measurement group_id="O2" value="2.062" spread="0.090"/>
                    <measurement group_id="O3" value="2.013" spread="0.091"/>
                    <measurement group_id="O4" value="1.838" spread="0.093"/>
                    <measurement group_id="O5" value="2.137" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.693" spread="0.092"/>
                    <measurement group_id="O2" value="2.136" spread="0.092"/>
                    <measurement group_id="O3" value="2.020" spread="0.093"/>
                    <measurement group_id="O4" value="1.872" spread="0.096"/>
                    <measurement group_id="O5" value="2.154" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.678" spread="0.091"/>
                    <measurement group_id="O2" value="2.127" spread="0.091"/>
                    <measurement group_id="O3" value="2.011" spread="0.092"/>
                    <measurement group_id="O4" value="1.899" spread="0.095"/>
                    <measurement group_id="O5" value="2.122" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.645" spread="0.091"/>
                    <measurement group_id="O2" value="2.074" spread="0.091"/>
                    <measurement group_id="O3" value="2.108" spread="0.092"/>
                    <measurement group_id="O4" value="1.844" spread="0.094"/>
                    <measurement group_id="O5" value="2.112" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.655" spread="0.091"/>
                    <measurement group_id="O2" value="2.131" spread="0.091"/>
                    <measurement group_id="O3" value="2.161" spread="0.092"/>
                    <measurement group_id="O4" value="1.844" spread="0.095"/>
                    <measurement group_id="O5" value="2.063" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.712" spread="0.094"/>
                    <measurement group_id="O2" value="2.148" spread="0.094"/>
                    <measurement group_id="O3" value="2.127" spread="0.095"/>
                    <measurement group_id="O4" value="1.859" spread="0.098"/>
                    <measurement group_id="O5" value="2.141" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.732" spread="0.095"/>
                    <measurement group_id="O2" value="2.081" spread="0.095"/>
                    <measurement group_id="O3" value="2.090" spread="0.096"/>
                    <measurement group_id="O4" value="1.906" spread="0.099"/>
                    <measurement group_id="O5" value="2.143" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.738" spread="0.096"/>
                    <measurement group_id="O2" value="2.060" spread="0.096"/>
                    <measurement group_id="O3" value="2.111" spread="0.097"/>
                    <measurement group_id="O4" value="1.899" spread="0.100"/>
                    <measurement group_id="O5" value="2.153" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.756" spread="0.097"/>
                    <measurement group_id="O2" value="2.074" spread="0.097"/>
                    <measurement group_id="O3" value="2.078" spread="0.098"/>
                    <measurement group_id="O4" value="1.872" spread="0.100"/>
                    <measurement group_id="O5" value="2.146" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.706" spread="0.099"/>
                    <measurement group_id="O2" value="2.105" spread="0.099"/>
                    <measurement group_id="O3" value="2.083" spread="0.100"/>
                    <measurement group_id="O4" value="1.896" spread="0.103"/>
                    <measurement group_id="O5" value="2.154" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.670" spread="0.101"/>
                    <measurement group_id="O2" value="2.084" spread="0.101"/>
                    <measurement group_id="O3" value="2.149" spread="0.102"/>
                    <measurement group_id="O4" value="1.975" spread="0.105"/>
                    <measurement group_id="O5" value="2.180" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.706" spread="0.098"/>
                    <measurement group_id="O2" value="2.103" spread="0.098"/>
                    <measurement group_id="O3" value="2.116" spread="0.099"/>
                    <measurement group_id="O4" value="1.928" spread="0.102"/>
                    <measurement group_id="O5" value="2.156" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.704" spread="0.098"/>
                    <measurement group_id="O2" value="2.124" spread="0.098"/>
                    <measurement group_id="O3" value="2.119" spread="0.099"/>
                    <measurement group_id="O4" value="1.928" spread="0.102"/>
                    <measurement group_id="O5" value="2.168" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.675" spread="0.098"/>
                    <measurement group_id="O2" value="2.056" spread="0.098"/>
                    <measurement group_id="O3" value="2.094" spread="0.099"/>
                    <measurement group_id="O4" value="1.959" spread="0.102"/>
                    <measurement group_id="O5" value="2.138" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.672" spread="0.100"/>
                    <measurement group_id="O2" value="2.114" spread="0.100"/>
                    <measurement group_id="O3" value="2.116" spread="0.101"/>
                    <measurement group_id="O4" value="1.961" spread="0.104"/>
                    <measurement group_id="O5" value="2.148" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation</title>
        <description>Physicians make a global evaluation reflecting the physician's global opinion of the overall clinical condition of the patient as &quot;poor&quot; (score 1 or 2), &quot;fair&quot; (score 3 or 4), &quot;good&quot; (score 5 or 6), or &quot;excellent&quot; (score 7 or 8). These assessments are made prior to pulmonary function testing and are summarized on pulmonary function test days. This evaluation was based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations. The score ranges from 1 to 8 with higher score indicating better overall clinical condition.</description>
        <time_frame>At Week 0, 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation</title>
          <description>Physicians make a global evaluation reflecting the physician's global opinion of the overall clinical condition of the patient as &quot;poor&quot; (score 1 or 2), &quot;fair&quot; (score 3 or 4), &quot;good&quot; (score 5 or 6), or &quot;excellent&quot; (score 7 or 8). These assessments are made prior to pulmonary function testing and are summarized on pulmonary function test days. This evaluation was based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations. The score ranges from 1 to 8 with higher score indicating better overall clinical condition.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.2"/>
                    <measurement group_id="O2" value="4.5" spread="1.2"/>
                    <measurement group_id="O3" value="4.5" spread="1.2"/>
                    <measurement group_id="O4" value="4.4" spread="1.2"/>
                    <measurement group_id="O5" value="4.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.541" spread="0.042"/>
                    <measurement group_id="O2" value="4.714" spread="0.042"/>
                    <measurement group_id="O3" value="4.747" spread="0.042"/>
                    <measurement group_id="O4" value="4.807" spread="0.044"/>
                    <measurement group_id="O5" value="4.739" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.582" spread="0.047"/>
                    <measurement group_id="O2" value="4.804" spread="0.047"/>
                    <measurement group_id="O3" value="4.790" spread="0.047"/>
                    <measurement group_id="O4" value="4.880" spread="0.048"/>
                    <measurement group_id="O5" value="4.816" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.613" spread="0.053"/>
                    <measurement group_id="O2" value="4.865" spread="0.053"/>
                    <measurement group_id="O3" value="4.775" spread="0.054"/>
                    <measurement group_id="O4" value="4.888" spread="0.055"/>
                    <measurement group_id="O5" value="4.810" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index - Functional Impairment Domain Score</title>
        <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of functional impairment is reported, which domain score ranges from -3 (major deterioration in the ability of working and doing activities due to shortness of breath; the worst score) to 3 (major improvement in the ability of working and doing activities; mild restriction on full activities due to the improvement of shortness of breath; the best score).</description>
        <time_frame>At Week 0 (baseline), 4, 12 and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index - Functional Impairment Domain Score</title>
          <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of functional impairment is reported, which domain score ranges from -3 (major deterioration in the ability of working and doing activities due to shortness of breath; the worst score) to 3 (major improvement in the ability of working and doing activities; mild restriction on full activities due to the improvement of shortness of breath; the best score).</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.9"/>
                    <measurement group_id="O2" value="2.3" spread="0.9"/>
                    <measurement group_id="O3" value="2.3" spread="0.9"/>
                    <measurement group_id="O4" value="2.2" spread="0.9"/>
                    <measurement group_id="O5" value="2.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" spread="0.048"/>
                    <measurement group_id="O2" value="0.379" spread="0.048"/>
                    <measurement group_id="O3" value="0.480" spread="0.049"/>
                    <measurement group_id="O4" value="0.518" spread="0.050"/>
                    <measurement group_id="O5" value="0.462" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.276" spread="0.052"/>
                    <measurement group_id="O2" value="0.474" spread="0.052"/>
                    <measurement group_id="O3" value="0.519" spread="0.053"/>
                    <measurement group_id="O4" value="0.454" spread="0.054"/>
                    <measurement group_id="O5" value="0.492" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.353" spread="0.054"/>
                    <measurement group_id="O2" value="0.465" spread="0.054"/>
                    <measurement group_id="O3" value="0.445" spread="0.055"/>
                    <measurement group_id="O4" value="0.465" spread="0.056"/>
                    <measurement group_id="O5" value="0.488" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index - Magnitude of Task Domain Score</title>
        <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of task is reported, which domain score ranges from -3 (major deterioration from baseline status; the worst score) to 3 (major improvement from baseline status; the best score).</description>
        <time_frame>At week 0 (baseline), 4, 12 and 24</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index - Magnitude of Task Domain Score</title>
          <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of task is reported, which domain score ranges from -3 (major deterioration from baseline status; the worst score) to 3 (major improvement from baseline status; the best score).</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                    <measurement group_id="O2" value="2.2" spread="0.8"/>
                    <measurement group_id="O3" value="2.2" spread="0.8"/>
                    <measurement group_id="O4" value="2.2" spread="0.8"/>
                    <measurement group_id="O5" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.245" spread="0.048"/>
                    <measurement group_id="O2" value="0.494" spread="0.048"/>
                    <measurement group_id="O3" value="0.538" spread="0.049"/>
                    <measurement group_id="O4" value="0.571" spread="0.050"/>
                    <measurement group_id="O5" value="0.489" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.282" spread="0.053"/>
                    <measurement group_id="O2" value="0.494" spread="0.053"/>
                    <measurement group_id="O3" value="0.587" spread="0.053"/>
                    <measurement group_id="O4" value="0.479" spread="0.054"/>
                    <measurement group_id="O5" value="0.523" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.322" spread="0.055"/>
                    <measurement group_id="O2" value="0.510" spread="0.055"/>
                    <measurement group_id="O3" value="0.513" spread="0.056"/>
                    <measurement group_id="O4" value="0.514" spread="0.057"/>
                    <measurement group_id="O5" value="0.496" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index - Magnitude of Effort Domain Score</title>
        <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of effort is reported, which sub-score ranges from -3 (severe decrease in effort from baseline to avoid shortness of breath. Activities now take 50-100% longer to complete than required at baseline; the worst score) to 3 (Able to do things with much greater effort than previously with few pauses. Activities may be performed 50- 100% more rapidly than at baseline; the best score).</description>
        <time_frame>At Week 0 (baseline), 4, 12 and 24</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR Inhalation Solution 50 Microgram (mcg)</title>
            <description>Inhalation of solution of 50 microgram (mcg) BEA 1280 BR (2 inhalations via Respimat® inhaler x 25 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR Inhalation Solution 100 Microgram (mcg)</title>
            <description>Inhalation of solution of 100 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 50 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR Inhalation Solution 200 Microgram (mcg)</title>
            <description>Inhalation of solution of 200 microgram (mcg) BEA 1280 BR (2 inhalations viaRespimat® inhaler x 100 mcg) for oral inhalation once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index - Magnitude of Effort Domain Score</title>
          <description>The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of effort is reported, which sub-score ranges from -3 (severe decrease in effort from baseline to avoid shortness of breath. Activities now take 50-100% longer to complete than required at baseline; the worst score) to 3 (Able to do things with much greater effort than previously with few pauses. Activities may be performed 50- 100% more rapidly than at baseline; the best score).</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="387"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.7"/>
                    <measurement group_id="O2" value="2.0" spread="0.8"/>
                    <measurement group_id="O3" value="2.0" spread="0.8"/>
                    <measurement group_id="O4" value="2.0" spread="0.7"/>
                    <measurement group_id="O5" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.048"/>
                    <measurement group_id="O2" value="0.437" spread="0.048"/>
                    <measurement group_id="O3" value="0.497" spread="0.049"/>
                    <measurement group_id="O4" value="0.478" spread="0.050"/>
                    <measurement group_id="O5" value="0.449" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.253" spread="0.054"/>
                    <measurement group_id="O2" value="0.423" spread="0.054"/>
                    <measurement group_id="O3" value="0.486" spread="0.054"/>
                    <measurement group_id="O4" value="0.460" spread="0.055"/>
                    <measurement group_id="O5" value="0.478" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.273" spread="0.057"/>
                    <measurement group_id="O2" value="0.458" spread="0.057"/>
                    <measurement group_id="O3" value="0.472" spread="0.058"/>
                    <measurement group_id="O4" value="0.502" spread="0.059"/>
                    <measurement group_id="O5" value="0.474" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>The St. George's Respiratory Questionnaire (SGRQ) is a well-established, self-completed tool measuring health-related quality of life in patients with diseases of airways obstruction on three aspects of symptoms, activity, and impacts. The total SGRQ score is reported, which ranges from 0 (the best score) to 100 (the worst score) with smaller score value indicating less limitations due to breathlessness and better quality of life.</description>
        <time_frame>At Week 0, 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>The St. George's Respiratory Questionnaire (SGRQ) is a well-established, self-completed tool measuring health-related quality of life in patients with diseases of airways obstruction on three aspects of symptoms, activity, and impacts. The total SGRQ score is reported, which ranges from 0 (the best score) to 100 (the worst score) with smaller score value indicating less limitations due to breathlessness and better quality of life.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="18.1"/>
                    <measurement group_id="O2" value="41.9" spread="17.5"/>
                    <measurement group_id="O3" value="42.5" spread="17.7"/>
                    <measurement group_id="O4" value="43.8" spread="18.8"/>
                    <measurement group_id="O5" value="43.1" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.969" spread="0.486"/>
                    <measurement group_id="O2" value="40.552" spread="0.484"/>
                    <measurement group_id="O3" value="39.865" spread="0.490"/>
                    <measurement group_id="O4" value="40.689" spread="0.506"/>
                    <measurement group_id="O5" value="40.706" spread="0.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.744" spread="0.575"/>
                    <measurement group_id="O2" value="40.293" spread="0.573"/>
                    <measurement group_id="O3" value="39.506" spread="0.580"/>
                    <measurement group_id="O4" value="40.368" spread="0.596"/>
                    <measurement group_id="O5" value="39.489" spread="0.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.993" spread="0.626"/>
                    <measurement group_id="O2" value="40.103" spread="0.624"/>
                    <measurement group_id="O3" value="40.058" spread="0.632"/>
                    <measurement group_id="O4" value="40.728" spread="0.651"/>
                    <measurement group_id="O5" value="39.547" spread="0.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) 8 Domain Scores at Baseline</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function (10 questions), role physical (4 questions), Bodily pain (2 questions), General physical health (5 questions), Vitality (4 questions), Social functioning (2 questions), role emotional (3 questions), and General mental health (5 questions). Each domain score is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the score value, the better the health condition.</description>
        <time_frame>At baseline (Week 0, Day 1 of treatment period).</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) 8 Domain Scores at Baseline</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function (10 questions), role physical (4 questions), Bodily pain (2 questions), General physical health (5 questions), Vitality (4 questions), Social functioning (2 questions), role emotional (3 questions), and General mental health (5 questions). Each domain score is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the score value, the better the health condition.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="24.5"/>
                    <measurement group_id="O2" value="51.4" spread="25.1"/>
                    <measurement group_id="O3" value="51.9" spread="24.2"/>
                    <measurement group_id="O4" value="49.1" spread="24.7"/>
                    <measurement group_id="O5" value="51.1" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="27.5"/>
                    <measurement group_id="O2" value="55.9" spread="27.5"/>
                    <measurement group_id="O3" value="53.3" spread="26.7"/>
                    <measurement group_id="O4" value="53.9" spread="27.7"/>
                    <measurement group_id="O5" value="54.9" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="26.6"/>
                    <measurement group_id="O2" value="68.6" spread="25.5"/>
                    <measurement group_id="O3" value="66.7" spread="26.7"/>
                    <measurement group_id="O4" value="67.1" spread="26.8"/>
                    <measurement group_id="O5" value="65.9" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General physical health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="18.5"/>
                    <measurement group_id="O2" value="49.2" spread="18.0"/>
                    <measurement group_id="O3" value="48.0" spread="18.7"/>
                    <measurement group_id="O4" value="48.5" spread="19.2"/>
                    <measurement group_id="O5" value="47.1" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="20.3"/>
                    <measurement group_id="O2" value="53.6" spread="20.1"/>
                    <measurement group_id="O3" value="53.4" spread="21.1"/>
                    <measurement group_id="O4" value="52.1" spread="20.3"/>
                    <measurement group_id="O5" value="51.8" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="24.0"/>
                    <measurement group_id="O2" value="76.2" spread="22.8"/>
                    <measurement group_id="O3" value="75.2" spread="24.4"/>
                    <measurement group_id="O4" value="74.3" spread="23.9"/>
                    <measurement group_id="O5" value="74.2" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="28.9"/>
                    <measurement group_id="O2" value="70.8" spread="28.1"/>
                    <measurement group_id="O3" value="69.3" spread="27.6"/>
                    <measurement group_id="O4" value="67.8" spread="29.6"/>
                    <measurement group_id="O5" value="68.5" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="19.2"/>
                    <measurement group_id="O2" value="70.4" spread="19.4"/>
                    <measurement group_id="O3" value="71.2" spread="19.3"/>
                    <measurement group_id="O4" value="68.5" spread="20.0"/>
                    <measurement group_id="O5" value="68.5" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Physical Function Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of physical function (based on 10 questions) is reported, which is the weighted sum of the questions in corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical function.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Physical Function Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of physical function (based on 10 questions) is reported, which is the weighted sum of the questions in corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical function.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.201" spread="0.726"/>
                    <measurement group_id="O2" value="51.831" spread="0.724"/>
                    <measurement group_id="O3" value="52.812" spread="0.732"/>
                    <measurement group_id="O4" value="52.961" spread="0.754"/>
                    <measurement group_id="O5" value="53.052" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.541" spread="0.806"/>
                    <measurement group_id="O2" value="52.561" spread="0.804"/>
                    <measurement group_id="O3" value="52.099" spread="0.813"/>
                    <measurement group_id="O4" value="53.716" spread="0.838"/>
                    <measurement group_id="O5" value="53.935" spread="0.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.624" spread="0.854"/>
                    <measurement group_id="O2" value="52.702" spread="0.851"/>
                    <measurement group_id="O3" value="51.631" spread="0.861"/>
                    <measurement group_id="O4" value="52.256" spread="0.887"/>
                    <measurement group_id="O5" value="54.191" spread="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Role Physical Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role limitations due to physical health problems (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitations in roles due to physical health problems.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Role Physical Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role limitations due to physical health problems (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitations in roles due to physical health problems.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.168" spread="0.962"/>
                    <measurement group_id="O2" value="57.326" spread="0.959"/>
                    <measurement group_id="O3" value="57.469" spread="0.969"/>
                    <measurement group_id="O4" value="56.898" spread="1.000"/>
                    <measurement group_id="O5" value="57.950" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.405" spread="0.986"/>
                    <measurement group_id="O2" value="57.271" spread="0.983"/>
                    <measurement group_id="O3" value="57.186" spread="0.993"/>
                    <measurement group_id="O4" value="56.938" spread="1.024"/>
                    <measurement group_id="O5" value="57.417" spread="0.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.138" spread="1.047"/>
                    <measurement group_id="O2" value="57.095" spread="1.044"/>
                    <measurement group_id="O3" value="54.934" spread="1.055"/>
                    <measurement group_id="O4" value="55.871" spread="1.087"/>
                    <measurement group_id="O5" value="57.020" spread="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Bodily Pain Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of bodily pain (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less severer the bodily pain.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Bodily Pain Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of bodily pain (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less severer the bodily pain.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.828" spread="1.024"/>
                    <measurement group_id="O2" value="68.184" spread="1.020"/>
                    <measurement group_id="O3" value="70.738" spread="1.031"/>
                    <measurement group_id="O4" value="66.439" spread="1.063"/>
                    <measurement group_id="O5" value="70.512" spread="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.749" spread="1.124"/>
                    <measurement group_id="O2" value="66.698" spread="1.120"/>
                    <measurement group_id="O3" value="70.316" spread="1.132"/>
                    <measurement group_id="O4" value="67.815" spread="1.167"/>
                    <measurement group_id="O5" value="70.300" spread="1.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.964" spread="1.162"/>
                    <measurement group_id="O2" value="66.610" spread="1.158"/>
                    <measurement group_id="O3" value="68.279" spread="1.171"/>
                    <measurement group_id="O4" value="66.887" spread="1.205"/>
                    <measurement group_id="O5" value="69.995" spread="1.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - General Physical Health Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general physical health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical health in general.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - General Physical Health Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general physical health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical health in general.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.187" spread="0.630"/>
                    <measurement group_id="O2" value="48.725" spread="0.628"/>
                    <measurement group_id="O3" value="50.929" spread="0.635"/>
                    <measurement group_id="O4" value="49.476" spread="0.656"/>
                    <measurement group_id="O5" value="50.609" spread="0.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.709" spread="0.679"/>
                    <measurement group_id="O2" value="48.402" spread="0.677"/>
                    <measurement group_id="O3" value="50.057" spread="0.685"/>
                    <measurement group_id="O4" value="49.482" spread="0.706"/>
                    <measurement group_id="O5" value="50.847" spread="0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.913" spread="0.718"/>
                    <measurement group_id="O2" value="48.520" spread="0.716"/>
                    <measurement group_id="O3" value="50.156" spread="0.724"/>
                    <measurement group_id="O4" value="49.816" spread="0.746"/>
                    <measurement group_id="O5" value="49.477" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Vitality Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of vitality (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the more vitality and less fatigue one has.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Vitality Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of vitality (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the more vitality and less fatigue one has.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.501" spread="0.716"/>
                    <measurement group_id="O2" value="53.516" spread="0.713"/>
                    <measurement group_id="O3" value="54.084" spread="0.721"/>
                    <measurement group_id="O4" value="53.630" spread="0.743"/>
                    <measurement group_id="O5" value="54.881" spread="0.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.676" spread="0.759"/>
                    <measurement group_id="O2" value="53.670" spread="0.756"/>
                    <measurement group_id="O3" value="53.947" spread="0.765"/>
                    <measurement group_id="O4" value="53.935" spread="0.788"/>
                    <measurement group_id="O5" value="55.317" spread="0.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.188" spread="0.804"/>
                    <measurement group_id="O2" value="52.892" spread="0.801"/>
                    <measurement group_id="O3" value="54.080" spread="0.810"/>
                    <measurement group_id="O4" value="54.211" spread="0.833"/>
                    <measurement group_id="O5" value="54.542" spread="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Social Functioning Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of Social functioning (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the social functioning.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Social Functioning Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of Social functioning (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the social functioning.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.574" spread="0.919"/>
                    <measurement group_id="O2" value="76.235" spread="0.916"/>
                    <measurement group_id="O3" value="76.418" spread="0.926"/>
                    <measurement group_id="O4" value="77.177" spread="0.954"/>
                    <measurement group_id="O5" value="77.053" spread="0.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.093" spread="0.982"/>
                    <measurement group_id="O2" value="76.801" spread="0.979"/>
                    <measurement group_id="O3" value="75.108" spread="0.989"/>
                    <measurement group_id="O4" value="75.798" spread="1.018"/>
                    <measurement group_id="O5" value="76.992" spread="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.440" spread="1.062"/>
                    <measurement group_id="O2" value="75.157" spread="1.059"/>
                    <measurement group_id="O3" value="74.295" spread="1.070"/>
                    <measurement group_id="O4" value="75.520" spread="1.102"/>
                    <measurement group_id="O5" value="73.993" spread="1.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - Role Emotional Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role emotional (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitation in roles due to emotional problems.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - Role Emotional Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of role emotional (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitation in roles due to emotional problems.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.365" spread="1.073"/>
                    <measurement group_id="O2" value="70.509" spread="1.070"/>
                    <measurement group_id="O3" value="70.473" spread="1.081"/>
                    <measurement group_id="O4" value="71.646" spread="1.115"/>
                    <measurement group_id="O5" value="71.313" spread="1.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.399" spread="1.108"/>
                    <measurement group_id="O2" value="70.213" spread="1.104"/>
                    <measurement group_id="O3" value="71.035" spread="1.116"/>
                    <measurement group_id="O4" value="69.505" spread="1.150"/>
                    <measurement group_id="O5" value="70.081" spread="1.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.168" spread="1.184"/>
                    <measurement group_id="O2" value="70.884" spread="1.180"/>
                    <measurement group_id="O3" value="68.756" spread="1.193"/>
                    <measurement group_id="O4" value="70.454" spread="1.228"/>
                    <measurement group_id="O5" value="69.259" spread="1.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-item-health Survey (SF-36) - General Mental Health Domain Score</title>
        <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general mental health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the mental health in general.</description>
        <time_frame>At Week 4, 12, and 24.</time_frame>
        <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>36-item-health Survey (SF-36) - General Mental Health Domain Score</title>
          <description>The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.&#xD;
The domain score of general mental health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the mental health in general.</description>
          <population>The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="379"/>
                <count group_id="O5" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.585" spread="0.649"/>
                    <measurement group_id="O2" value="71.056" spread="0.646"/>
                    <measurement group_id="O3" value="70.927" spread="0.653"/>
                    <measurement group_id="O4" value="71.038" spread="0.674"/>
                    <measurement group_id="O5" value="71.281" spread="0.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.201" spread="0.743"/>
                    <measurement group_id="O2" value="70.320" spread="0.740"/>
                    <measurement group_id="O3" value="70.362" spread="0.748"/>
                    <measurement group_id="O4" value="71.466" spread="0.772"/>
                    <measurement group_id="O5" value="71.048" spread="0.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.144" spread="0.758"/>
                    <measurement group_id="O2" value="70.012" spread="0.755"/>
                    <measurement group_id="O3" value="69.868" spread="0.764"/>
                    <measurement group_id="O4" value="70.904" spread="0.788"/>
                    <measurement group_id="O5" value="69.286" spread="0.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Number of patients with at least one Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
        <time_frame>From first does until 30 days after the end of treatment, up to 205 days.</time_frame>
        <population>Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Number of patients with at least one Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
          <population>Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="419"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="390"/>
                <count group_id="O5" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
        <time_frame>From first does until 30 days after the end of treatment, up to 205 days.</time_frame>
        <population>Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BEA 2180 BR 50 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BEA 2180 BR 100 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BEA 2180 BR 200 Microgram (mcg)</title>
            <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium Bromide 5 Microgram (mcg)</title>
            <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as &quot;a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment&quot;, where a &quot;complex of lower respiratory events / symptoms&quot; means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.</description>
          <population>Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</population>
          <units>Events per patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="419"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="390"/>
                <count group_id="O5" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5797"/>
                    <measurement group_id="O2" value="0.4345"/>
                    <measurement group_id="O3" value="0.4898"/>
                    <measurement group_id="O4" value="0.4373"/>
                    <measurement group_id="O5" value="0.5332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first does until 30 days after the end of treatment, up to 205 days.</time_frame>
      <desc>Treated set: the treated set was defined as all patients who were randomized and who took at least one dose of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral inhalation of solution of Placebo matching BEA 2180 BR was administered once daily via Respimat® inhaler for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>BEA 2180 BR 50 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 25 micrograms (mcg) of BEA 2180 BR (total: 50 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>BEA 2180 BR 100 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 50 micrograms (mcg) of BEA 2180 BR (total: 100 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>BEA 2180 BR 200 Microgram (mcg)</title>
          <description>2 oral inhalations of solution of 100 micrograms (mcg) of BEA 2180 BR (total: 200 mcg) were administered via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Tiotropium Bromide 5 Microgram (mcg)</title>
          <description>2 inhalation of solution of 2.5 micrograms (mcg) of Tiotropium Bromide (total: 5 mcg) were administered orally via Respimat® inhaler once daily for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Endometrial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tracheal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pharyngeal ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Aortic bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="419"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="390"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.&#xD;
Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.&#xD;
BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

